NEW YORK / Apr 27, 2023 / Business Wire / Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the closing of its previously announced public offering of 1,265,000 common shares at $71.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 165,000 additional common shares. The gross proceeds to the Company were approximately $90.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.

The Company intends to use the net proceeds from this offering, together with its existing cash, for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.

Jefferies, J.P. Morgan, Citigroup and TD Cowen acted as joint book-running managers for the offering. BTIG acted as co-manager.

The offering was made pursuant to a prospectus supplement, dated April 24, 2023, to the accompanying prospectus included in the Company’s automatically effective shelf registration statement on Form S-3 (File No. 333-271418), which was filed on April 24, 2023. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it.; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at This email address is being protected from spambots. You need JavaScript enabled to view it.; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at This email address is being protected from spambots. You need JavaScript enabled to view it. or by telephone at (833) 297-2926.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the 85 countries in which they are available. The Motiva Flora® tissue expander is the only regulatory-approved expander in the world with an integrated port that is MRI conditional and is used to improve outcomes in breast reconstruction following breast cancer. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patents and patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States.